Detalhe da pesquisa
1.
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Headache
; 63(6): 730-742, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37313616
2.
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
Cephalalgia
; 42(2): 108-118, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34743579
3.
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Headache
; 62(5): 624-633, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35593783
4.
Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
J Headache Pain
; 23(1): 104, 2022 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35978286
5.
Miniaturization, Parallelization, and Automation of Endotoxin Detection by Centrifugal Microfluidics.
Anal Chem
; 93(24): 8508-8516, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34100587
6.
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study.
J Neurol Neurosurg Psychiatry
; 92(5): 466-472, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33402419
7.
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
Cephalalgia
; 41(1): 33-44, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231489
8.
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
Cephalalgia
; 41(11-12): 1152-1160, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33982623
9.
Timing and durability of response to erenumab in patients with episodic migraine.
Headache
; 61(10): 1553-1561, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34841526
10.
Timing and durability of response to erenumab in patients with chronic migraine.
Headache
; 61(8): 1255-1263, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363708
11.
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
J Headache Pain
; 22(1): 81, 2021 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301173
12.
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
Cephalalgia
; 40(1): 28-38, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816249
13.
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
Headache
; 60(9): 2026-2040, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32851644
14.
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Lancet
; 392(10161): 2280-2287, 2018 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360965
15.
Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed.
Cephalalgia
; 39(5): 608-616, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30231626
16.
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Cephalalgia
; 39(7): 817-826, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982348
17.
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
Cephalalgia
; 39(14): 1798-1808, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707815
18.
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
Cephalalgia
; 39(11): 1455-1464, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146544
19.
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Cephalalgia
; 38(10): 1611-1621, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984601
20.
Early onset of efficacy with erenumab in patients with episodic and chronic migraine.
J Headache Pain
; 19(1): 92, 2018 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30276500